Peer-reviewed veterinary case report
All parts of the interleukin-2 receptor found in dog skin mast cell
By Meyer, A et al.·Published in Journal of comparative pathology·2013·Department of Veterinary Pathology, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
- Species:
- dog
Plain-English summary
A study found that most dogs with skin tumors called cutaneous mast cell tumors (MCTs) showed signs of certain proteins related to the immune system. Specifically, 86% of the tumors had two parts of the interleukin-2 receptor (IL-2R), which is involved in cell growth and immune responses. Interestingly, higher-grade tumors, which are more aggressive, had lower levels of these proteins. This suggests that the IL-2R might play a role in the early development of these tumors. Understanding this could help in finding better treatments for dogs with MCTs.
People also search for: dog skin tumor treatment · mast cell tumor in dogs · canine cutaneous mast cell tumor symptoms
Abstract
Cutaneous mast cell tumours (MCTs) are among the most important skin tumours in dogs. Apart from c-KIT mutations, which are present in <18% of MCTs, little is known of the mechanisms of MCT development and independent growth of tumour cells. Recently, the α-subunit (CD25) of the interleukin (IL)-2 receptor (IL-2R) has been found to be expressed by canine cutaneous MCTs and this expression is negatively correlated with tumour grade. We thus hypothesized that the other two subunits of the IL-2R and the ligand IL-2 are also expressed and that IL-2-dependent pathways may have an impact on MCT development and independent tumour cell growth. Messenger RNA and protein expression levels of the IL-2R β-subunit (CD122), the IL-2R γ-subunit (CD132) and IL-2 were analyzed in canine cutaneous MCTs and compared with tumour grade and c-KIT mutation status. Eighty-six percent of the tumours expressed both subunits of the IL-2R and 64% expressed IL-2. In addition, neoplastic mast cells seem able to bind IL-2. IL-2Rγ and IL-2 protein expression levels were significantly decreased in higher grade tumours and IL-2 expression was significantly decreased in c-KIT mutated tumours. Thus, expression of the complete IL-2R and its ligand by canine cutaneous MCTs indicates a potential impact of IL-2R signalling in MCT development and tumour cell proliferation. The decrease in IL-2R expression with increasing histological evidence of malignancy suggests that the IL-2R may be more relevant for early MCT development and well-differentiated tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23276382/